QV Investors Inc. lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 95.9% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,510 shares of the company’s stock after selling 35,055 shares during the quarter. QV Investors Inc.’s holdings in Johnson & Johnson were worth $196,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of JNJ. Harding Loevner LP acquired a new stake in shares of Johnson & Johnson during the second quarter worth about $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. lifted its position in shares of Johnson & Johnson by 29.9% during the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock worth $115,000 after purchasing an additional 200 shares in the last quarter. Lenox Wealth Advisors Inc. lifted its position in shares of Johnson & Johnson by 0.6% during the second quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock worth $116,000 after purchasing an additional 5 shares in the last quarter. IHT Wealth Management LLC lifted its position in shares of Johnson & Johnson by 46.4% during the second quarter. IHT Wealth Management LLC now owns 10,942 shares of the company’s stock worth $122,000 after purchasing an additional 3,467 shares in the last quarter. Finally, Mountain Capital Investment Advisors Inc acquired a new stake in shares of Johnson & Johnson during the second quarter worth about $124,000. 65.71% of the stock is currently owned by institutional investors and hedge funds.

JNJ has been the topic of several research reports. Cowen reissued an “outperform” rating and set a $155.00 price target (up previously from $147.00) on shares of Johnson & Johnson in a research report on Wednesday, October 18th. Jefferies Group upped their target price on shares of Johnson & Johnson from $157.00 to $160.00 and gave the stock a “buy” rating in a research note on Monday, October 16th. Zacks Investment Research upgraded shares of Johnson & Johnson from a “sell” rating to a “hold” rating in a research note on Wednesday, October 4th. Credit Suisse Group set a $154.00 target price on shares of Johnson & Johnson and gave the stock an “outperform” rating in a research note on Thursday, October 19th. Finally, Barclays upped their target price on shares of Johnson & Johnson from $140.00 to $148.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 18th. Four research analysts have rated the stock with a sell rating, seven have assigned a hold rating and eleven have issued a buy rating to the company. Johnson & Johnson has an average rating of “Hold” and an average target price of $145.94.

Johnson & Johnson (NYSE:JNJ) opened at $147.36 on Friday. The company has a market cap of $395,885.59, a P/E ratio of 20.64, a price-to-earnings-growth ratio of 2.76 and a beta of 0.80. Johnson & Johnson has a one year low of $110.76 and a one year high of $148.32. The company has a quick ratio of 1.02, a current ratio of 1.32 and a debt-to-equity ratio of 0.36.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 13th. Shareholders of record on Tuesday, February 27th will be paid a $0.84 dividend. The ex-dividend date is Monday, February 26th. This represents a $3.36 annualized dividend and a yield of 2.28%. Johnson & Johnson’s dividend payout ratio is currently 58.33%.

WARNING: “QV Investors Inc. Trims Stake in Johnson & Johnson (JNJ)” was published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this article on another website, it was illegally stolen and reposted in violation of US & international copyright law. The legal version of this article can be viewed at https://theolympiareport.com/2018/01/21/qv-investors-inc-trims-stake-in-johnson-johnson-jnj.html.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.